



TETRA BIO-PHARMA

Global Leaders in Cannabinoid-Based Drug Discovery and Development

Value Creating Milestones

December 30, 2020

Value Creating Milestones

2020 – Milestone Status

ARDS-003

- Completion of intravenous finished drug product for human trials.
 - **Completed; NR dated August 18th.**
- Completion of clinical batch IND-enabling toxicology with no safety issues for proceeding to humans.
 - **Completed; Nov 16th & Dec 2nd NR.**
- File CTA/IND of Phase 1 trial.
 - **Initiated regulatory process.**

QIXLEEF

- Initiate PLENITUDE (Phase II) in advanced cancer patients with uncontrolled pain in USA.
 - **Trial launched; NR dated Sept 2nd.**
- File EU Phase 3 Plenitude trial in cancer pain.
 - **Trial implementation; NR dated Nov 16th.**

Ophthalmic

- File CTA/IND of Phase 1 trial
 - **Initiated regulatory process.**

CAUMZ

- Initiate Phase 3 enabling toxicology.
 - **Studies initiated.**
- File IND THC-CBD interactions trials required for NDA.
 - **Initiated regulatory process.**
- File IND for Reborn trial.
 - **Refer to Nov. 16th NR.**
- File IND for trial in advanced cancer patients.
 - **Initiated regulatory process.**

QIXLEEF & CAUMZ:

- Complete mapping of cannabinoid metabolites
 - **Completed; Nov 16th NR.**

Dronabinol NDS filing

- New Drug Submission filing to Health Canada
 - **Completed; Dec 30th NR.**